Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Placental-derived autologous mesenchymal stem cells (MSCs) are an experimental cell therapy being investigated for the treatment of bronchopulmonary dysplasia (BPD) in premature infants. The therapy involves isolating MSCs from the infant's own placenta, expanding them in vitro, and subsequently re-administering them to the same infant via intravenous infusion. These cells are hypothesized to exert therapeutic effects by migrating to injured lung tissue and secreting a variety of paracrine factors, including anti-inflammatory cytokines and growth factors, which promote tissue repair, reduce inflammation, and support angiogenesis in the developing neonatal lung.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on placental-derived autologous mesenchymal stem cells.